[SCHEDULE 13G/A] Cardiff Oncology, Inc. SEC Filing

Rhea-AI Filing Summary

Cardiff Oncology, Inc. (CRDF) received a joint Schedule 13G/A from Commodore Capital LP and Commodore Capital Master LP reporting zero beneficial ownership of the issuer's common stock (CUSIP 14147L108). The filing lists each filers jurisdiction (Delaware and Cayman Islands), business addresses, and certifies the securities were not acquired to influence control of the company. The cover pages show 0.00 shares and 0.0% of the class for both filers. The document includes a signed joint filing agreement and certifications by Michael Kramarz as Managing Partner and Authorized Signatory.

Positive

• Full disclosure by both filers including addresses and certifications
• Joint Filing Agreement included and signatures present, indicating procedural completeness

Negative

• No beneficial ownership reported (0.00 shares, 0.0%), so filers hold no economic or voting influence

Insights

Securities Analyst

TL;DR: Routine disclosure showing no holdings; therefore no investor influence or activist intent.

This Schedule 13G/A is a standard transparency filing. Both Commodore entities explicitly report 0.00 shares (0.0%) beneficially owned, and the certification asserts the securities were not acquired to influence control. For investors, the filing conveys that these named filers currently have no economic stake or voting influence in Cardiff Oncology, so it should not affect shareholder dynamics or control considerations.

Compliance / Corporate Governance Expert

TL;DR: Compliance-complete filing: required disclosures made and signed, with no material ownership reported.

The submission includes required identifying information, jurisdictional details, and a signed joint filing agreement. The explicit declaration of zero ownership and the certification language satisfy disclosure obligations under Schedule 13G/A. There are no indications of omitted items in the text provided.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Cardiff Oncology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

14147L108

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 14147L108

1

Names of Reporting Persons

Commodore Capital LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 14147L108

1

Names of Reporting Persons

Commodore Capital Master LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cardiff Oncology, Inc.
(b)	Address of issuer's principal executive offices: 11055 Flintkote Avenue, San Diego, CALIFORNIA, 92121.
Item 2.
(a)	Name of person filing: Commodore Capital LP Commodore Capital Master LP Each a "Filer."
(b)	Address or principal business office or, if none, residence: The address for Commodore Capital LP is 444 Madison Avenue, Floor 35, New York, NY 10022. The address for Commodore Capital Master LP is c/o Maples Corporate Services Limited, Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands.
(c)	Citizenship: See Item 4 of the cover page for each Filer.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 14147L108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 of the cover page for each Filer.
(b)	Percent of class: See Item 11 of the cover page for each Filer.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 of the cover page for each Filer.
	(ii) Shared power to vote or to direct the vote: See Item 6 of the cover page for each Filer.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 of the cover page for each Filer.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 of the cover page for each Filer.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Commodore Capital LP

Signature:	Michael Kramarz
Name/Title:	Managing Partner
Date:	08/14/2025

Commodore Capital Master LP

Signature:	Michael Kramarz
Name/Title:	Authorized Signatory
Date:	08/14/2025

Exhibit Information

Exhibit 1: Joint Filing Agreement

FAQ

What does the Schedule 13G/A filed for Cardiff Oncology (CRDF) report?

The filing reports that Commodore Capital LP and Commodore Capital Master LP beneficially own 0.00 shares (0.0%) of Cardiff Oncology common stock.

Who signed the Schedule 13G/A for Commodore Capital regarding CRDF?

Michael Kramarz signed as Managing Partner for Commodore Capital LP and as Authorized Signatory for Commodore Capital Master LP on 08/14/2025.

Does this filing indicate the filers intend to influence control of Cardiff Oncology (CRDF)?

No. The certification states the securities were not acquired and are not held to change or influence control of the issuer.

What jurisdictions are the filers organized in for the CRDF 13G/A?

Commodore Capital LP is organized in Delaware and Commodore Capital Master LP is organized in the Cayman Islands.

Is there any percent ownership reported that could trigger 5% ownership disclosure thresholds for CRDF?

No. Both filers report 0.0%, which is well below any 5% threshold.